Evidence map›Paper›PMID 31798282›Full record

ArticleWorld journal of gastroenterology2019

Metabolic syndrome attenuates ulcerative colitis: Correlation with interleukin-10 and galectin-3 expression.

Marina Jovanovic, Bojana Simovic Markovic, Nevena Gajovic, Milena Jurisevic, Aleksandar Djukic, Ivan Jovanovic, Nebojsa Arsenijevic, Aleksandra Lukic, Natasa Zdravkovic

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Marina JovanovicDepartment of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia.
Bojana Simovic MarkovicCenter for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia. bojana.simovicmarkovic@medf.kg.ac.rs.
Nevena GajovicCenter for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia.
Milena JurisevicDepartment of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia.
Aleksandar DjukicDepartment of Pathophysiology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia.
Ivan JovanovicCenter for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia.
Nebojsa ArsenijevicCenter for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia.
Aleksandra LukicDepartment of Dentistry, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia.
Natasa ZdravkovicDepartment of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia.
University of Kragujevac · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUlcerative colitis (UC) is a chronic disease characterized by inflammation of intestinal epithelium, primarily of the colon. An increasing prevalence of metabolic syndrome (MetS) in patients with UC has been documented recently. Still, there is no evidence that MetS alters the course of the UC.

aimTo test the influence of the MetS on the severity of UC and the local and systemic immune status.

methodsEighty nine patients with

resultsClinically and histologically milder disease with higher serum level of immunosuppressive cytokine interleukin-10 (IL-10) and fecal content of Galectin-3 (Gal-3) was observed in subjects with UC and MetS, compared to subjects suffering from UC only. This was accompanied with predomination of IL-10 over pro-inflammatory cytokines tumor necrosis factor α (TNF-α), interleukin-6 (IL-6), and interleukin-17 (IL-17) in the sera as well as Gal-3 over TNF-α and IL-17 in feces of UC patients with MetS. Further, the patients with both conditions (UC and MetS) had higher percentage of IL-10 producing and Gal-3 expressing innate and acquired immune cells in lamina propria.

conclusionLocal dominance of Gal-3 and IL-10 over pro-inflammatory mediators in patients with MetS may present a mechanism for limiting the inflammatory process and subsequent tissue damage in UC.

Indexed as

AdultAgedAged, 80 and overBlood ProteinsCase-Control StudiesColitis, UlcerativeColonCytokinesFecesFemaleGalectin 3GalectinsHumansLymphocytesMaleMetabolic SyndromeBlood ProteinsCytokinesGalectin 3GalectinsLGALS3 protein, humanGalectin-3InflammationInterleukin-10Metabolic syndromeSystemic immune responseUlcerative colitis

Identifiers

PMID31798282
PMCPMC6881509
OpenAlexW2991481115

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.